Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients (COBETOX)
COVID19, BETA-CELL FUNCTION
About this trial
This is an interventional diagnostic trial for COVID19
Eligibility Criteria
Inclusion criteria for COVID-19 positive patients
- Male and female patients with COVID19 and normal basal blood sugar, unprecedented in diabetes or impaired fasting glucose or impaired glucose tolerance
- Age> 18 years and <80 years
- Availability to informed consent and corporate privacy
Inclusion criteria for healthy subjects
- Male and female patients not affected by COVID19, unprecedented in diabetes or impaired fasting glucose or impaired glucose tolerance
- Age> 18 years and <80 years
- Availability to informed consent and corporate privacy
Exclusion criteria for COVID-19 positive patients
- Age <18 years
- Previous history of diabetes or impaired fasting glucose or impaired glucose tolerance
- Severe liver failure
- Severe kidney failure
Exclusion criteria for healthy subjects
- Age <18 years
- Previous history of diabetes or impaired fasting glucose or impaired glucose tolerance
- Positivity to the nasopharyngeal swab for SARS-CoV-2
- Severe liver failure
- Severe kidney failure
Inclusion criteria for T2D patients
- Male and female patients not affected by COVID19 with a diagnosis of type 2 diabetes
- Age> 18 years and <80 years
- Availability to informed consent and corporate privacy
Exclusion criteria for T2D patients
- Age <18 years
- Positivity to the nasopharyngeal swab for SARS-CoV-2
- Severe liver failure
- Severe kidney failure
Sites / Locations
- Sacco University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Other
Other
COVID-19 positive patients
Healthy volunteers
Type 2 diabetes patients
Patients will be enrolled in hospital for confirmed COVID-19 infection (with reverse transcriptase-polymerase chain reaction on the airway swab) but with normal basal glucose and no previous history of diabetes or impaired fasting glucose or impaired tolerance glucose. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
Healthy volunteers, not affected by COVID-19 and with no previous history of diabetes or impaired fasting glucose or impaired glucose tolerance will be enrolled. Healthy volunteers will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
Patients with established Type 2 diabetes, not affects by COVID-19. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.